Roflumilast is the only phosphodiesterase 4 inhibitor approved for the treatment of COPD patients with chronic cough and sputum, and a history of exacerbations, but the compliance to treatment is reduced by poorly tolerated adverse events (AEs).
Rogliani, P., Calzetta, L., Cazzola, M., Matera, M. (2016). Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. EXPERT OPINION ON DRUG SAFETY, 15(8), 1133-1146 [10.1080/14740338.2016.1199683].
Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis
ROGLIANI, PAOLA;CAZZOLA, MARIO;
2016-01-01
Abstract
Roflumilast is the only phosphodiesterase 4 inhibitor approved for the treatment of COPD patients with chronic cough and sputum, and a history of exacerbations, but the compliance to treatment is reduced by poorly tolerated adverse events (AEs).File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
